Retinopathy - Pipeline Review, H1 2012

Description:
Retinopathy – Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Retinopathy - Pipeline Review, H1 2012', provides an overview of the Retinopathy therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. 'Retinopathy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinopathy.
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Retinopathy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Retinopathy Therapeutic Products under Development, Key Players in Retinopathy Therapeutics, Retinopathy Pipeline Overview, Retinopathy Pipeline, Retinopathy Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinopathy Overview
Therapeutics Development
An Overview of Pipeline Products for Retinopathy
Retinopathy Therapeutics under Development by Companies
Retinopathy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Retinopathy Therapeutics – Products under Development by Companies
Retinopathy Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Retinopathy Therapeutics Development
NsGene A/S
Compugen Ltd.
Acucela Inc.
Gene Signal International SA.
Indus Biotech Private Limited
Affichem
Resolvyx Pharmaceuticals, Inc
SIFI Pharma
EyeGene, Inc.
Retinopathy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Drug For Retinopathy Of Prematurity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CGEN-25017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AF-243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INDUS815C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-10001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF 113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Propranolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mecasermin Rinfabate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myo-Inositol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimmune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG-Mitorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinopathy Therapeutics – Drug Profile Updates
Retinopathy Therapeutics - Dormant Products
Retinopathy - Product Development Milestones
Featured News & Press Releases
May 08, 2012: Gene Signal Presents Preclinical Data Of Aganirsen At ARVO Annual Meeting
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Retinopathy, H1 2012
Products under Development for Retinopathy – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
NsGene A/S, H1 2012
Compugen Ltd., H1 2012
Acucela Inc., H1 2012
Gene Signal International SA., H1 2012
Indus Biotech Private Limited, H1 2012
Affichem, H1 2012
Resolvyx Pharmaceuticals, Inc, H1 2012
SIFI Pharma, H1 2012
EyeGene, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Retinopathy Therapeutics – Drug Profile Updates
Retinopathy Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Retinopathy, H1 2012
Products under Development for Retinopathy – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Retinopathy - Pipeline Review, H1 2012 |
| Web Address: | http://www.researchandmarkets.com/reports/2167198/ |
| Office Code: | SCD2ILC6 |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 500</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World